Tilaxin - instructions for use, dose, side effects, contraindications

Excipients: basic magnesium carbonate, talc, povidone (polyvinylpyrrolidone, low molecular weight Medical), calcium stearate - sufficient quantity to yield a tablet weighing 0.1 g (without sheath);

Excipients: sucrose (sugar), magnesium carbonate basic, povidone (polyvinylpyrrolidone, low molecular weight Medical), talc, colloidal silicon dioxide (Aerosil), titanium dioxide, tropeolin O, gelatin medical, beeswax Pasechnaya - sufficient quantity to obtain a coated tablet by capacity, mass 0.2 g.

One tablet, coated. 125 mg contains:

Active substance: tilaxine (tilorone) 0.125 g.

Excipients: magnesium hydroxycarbonate, talc, povidone (polyvinylpyrrolidone low molecular weight medical), calcium stearate - a sufficient amount to obtain a tablet weighing 0.2 g (without shell);

Excipients: sucrose (sugar), magnesium hydroxycarbonate (magnesium carbonate basic), povidone (polyvinylpyrrolidone low molecular weight medical), talc, silicon dioxide colloid (aerosil), titanium dioxide, tropeolin dye O, gelatin medical, beeswax, paraffin liquid (vaseline oil) - sufficient amount to obtain a tablet coated with a build-up method, weighing 0.39 g.

Description:

Tablets of 60 mg: tablets covered with a cover from light yellow to yellow color, round, biconcave. The core of the tablet is orange.

Tablets 125 mg: tablets, coated with a yellow color, round,

biconvex. On the break, the tablets are orange.

Pharmacotherapeutic group:antiviral immunostimulating means - inducer of the formation of interferons.

ATX: & nbsp

L.03.A.X Other immunostimulants

Pharmacodynamics:

A low molecular weight synthetic interferon inducer that stimulates the formation of alpha, beta and gamma interferons in the body. The main producers of interferon in response to the introduction of Tyloron are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes. After oral administration, the maximum production of interferon is determined in the sequence of the intestine - liver - blood after 4-24 hours. Amiksin ® has an immunomodulatory and antiviral effect.

In human leukocytes induces the synthesis of interferon. Stimulates bone marrow stem cells, depending on the dose, enhances antibody formation, reduces the degree of immunosuppression, restores the ratio of T-suppressors and T-helpers. Effective against various viral infections, including against influenza viruses, other acute respiratory viral infections, hepatitis viruses and herpesviruses. The mechanism of antiviral action is associated with the inhibition of the translation of virus-specific proteins in infected cells, as a result of which the reproduction of viruses is suppressed.

Pharmacokinetics:

After oral administration, it is rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%. About 80% of the drug binds to plasma proteins.The drug is practically unchanged through the intestine (70%) and through the kidneys (9%). The half-life (T1 / 2) is 48 hours. The drug is not biotransformed and does not accumulate in the body.

Indications:

Indications for use

In adults, treatment and prevention of influenza, other SARS, treatment of viral hepatitis A, B and C, treatment of herpetic and cytomegalovirus infection; in the complex therapy of infectious-allergic and viral encephalomyelitis (multiple sclerosis, panencephalitis, uveoentsefalit et al.), in combined therapy of respiratory and urogenital Chlamydia, in the treatment of pulmonary tuberculosis;

In children, older than 7 years - to treat influenza and other ARVI.

Contraindications:

Hypersensitivity to the drug.

Pregnancy and lactation.

Children under 7 years.

Dosing and Administration:

take inside, after eating.

For the treatment of viral hepatitis A - 125 mg twice a day on the first day, then 125 mg after 48 hours. The course - 1.25 g (10 tablets).

For the treatment of acute hepatitis B - the first two days of 125 mg, then 125 mg after 48 hours, for treatment - 2 g (16 tablets). With prolonged course of hepatitis B, 125 mg twice a day on the first day, then 125 mg after 48 hours.The course of treatment - 2.5 g (20 tablets).

With chronic hepatitis B - the initial phase of treatment (2.5 g - 20 tablets) - the first two days for 125 mg 2 times a day, then 125 mg after 48 hours. The continuation phase (from 1.25 g - 10 tablets to 2.5 g - 20 tablets) - 125 mg per week. The course dose of Amiksin® is from 3.75 g to 5 g, the duration of therapy is 3.5-6 months, depending on the results of biochemical, immunological, morphological studies reflecting the degree of activity of the process.

In acute hepatitis C, 125 mg per day for the first 2 days of treatment, then 125 mg after 48 hours. The course of treatment is 2.5 g (20 tablets).

In chronic hepatitis C - the initial phase of treatment (2.5 g - 20 tablets) - the first two days of 125 mg 2 times a day, then 125 mg after 48 hours. The continuation phase (2.5 g - 20 tablets) - 125 mg per week. The course dose of Amiksin® is 5 g, the duration of therapy is 6 months, depending on the results of biochemical, immunological, and morphological markers of the activity of the process.

In the complex treatment of neuroviral infections - 125-250 mg per day for the first 2 days of treatment, then 125 mg after 48 hours. The dose is set individually, the course of treatment is 3-4 weeks.

For treatment of influenza and other acute respiratory viral infections, 125 mg daily for the first 2 days of treatment, then 125 mg after 48 hours. On the course - 750 mg (6 tablets).

For the prevention of influenza and other acute respiratory viral infections, 125 mg once a week for 6 weeks. On the course - 750 mg (6 tablets).

For treatment of herpetic, cytomegalovirus infection - the first two days of 125 mg, then 48 hours after 125 mg. The course dose is 1.25 - 2.5 g (10 - 20 tablets).

With urogenital and respiratory chlamydia - the first two days of 125 mg, then 48 hours after 125 mg. The course dose is 1.25 g (10 tablets).

With the complex therapy of pulmonary tuberculosis - 250 mg the first two days of treatment, then 125 mg after 48 hours. The course dose is 2.5 g (20 tablets).

In children older than 7 years with uncomplicated forms of influenza and other acute respiratory viral infections, 60 mg once a day on the 1st, 2nd and 4th days after the start of treatment. The course dose is 180 mg (3 tablets). When complications of influenza or other acute respiratory viral infections occur, 60 mg once a day on the 1st, 2nd, 4th and 6th days from the start of treatment. The course dose is 0.24 g (4 tablets).

Side effects:Allergic reactions, dyspeptic phenomena, short-term chills are possible.

Overdose:

Cases of drug overdose are not known.

Interaction:

Compatible with antibiotics and drugs traditional treatment of viral and bacterial diseases. Clinically significant effects of Amiksin® with antibiotics and traditional treatments for viral and bacterial diseases have not been identified.

Form release / dosage:

Tablets coated with 60 mg and 125 mg.

Packaging:For 10 tablets in a planar cell pack of PVC film and aluminum foil; on 6 or 10 tablets in cans of polymeric with the control of opening.

1 contour mesh package or 1 can of polymer with instructions for use in a pack of cardboard.

Storage conditions:

List B. In dry the dark place at a temperature of +5 to +30 ° C.

Keep out of the reach of children.

Terms of leave from pharmacies:

Without a prescription - tablets 125 mg, coated.

Prescription - 60 mg tablets, coated with a shell.

Shelf life:

3 years. Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N000816 / 02

Date of registration:29.10.2008

The owner of the registration certificate:DALHIMFARM, OJSC DALHIMFARM, OJSC Russia

Manufacturer: & nbsp

DALHIMFARM, OJSC Russia

Representation: & nbspDALHIMFARM, OJSCDALHIMFARM, OJSC

Information update date: & nbsp30.08.2015

Illustrated instructions

Instructions

Tilaxin® (Tilaxin)